Introduction: Gastrointestinal (GI) vasculitis among systemic lupus erythematosus (SLE) patients is a rare manifestation confounded with non-specific clinical symptoms and laboratory parameters which delay diagnosis leading to increase morbidity and mortality. This is a case report of a patient with of GI vasculitis who was successfully treated with belimumab Case presentation: We describe a case of a Chinese descent, 24-year-old female who was diagnosed with SLE presenting as malar rash, arthritis, intermittent fever, positive antinuclear antibody (ANA), high titer anti double-stranded DNA and low serum complement. She had gastrointestinal manifestations of colicky abdominal pain, vomiting and diarrhea, with computed tomography scan findings of diffuse mucosal edema involving both small and large intestines, with “target” sign strongly suggestive of GI vasculitis. She initially showed good response to methylprednisolone pulse therapy, but with recurrence of abdominal pain after three months. Repeat abdominal CT showed perforated viscus at the ileal segment with pneumoperitoneum, requiring emergency exploratory laparotomy and colostomy placement. Subsequent clinical course was marked by intolerance to oral steroid requiring regular administration of high dose intravenous steroids. Belimumab was started months after surgery and maintained for two years now. She was successfully shifted to oral prednisone, tapered to lowest dose and underwent uneventful intestinal reanastomosis with closure of colostomy. Discussion: Gastrointestinal (GI) vasculitis is one of the most serious gastrointestinal complications SLE presenting as acute abdominal pain. Our patient was diagnosed based on abdominal CT scan which led to an accurate diagnosis and prompt treatment. Supportive measures, surgery, and belimumab impacted the outcome of this patient. Conclusion Gastrointestinal (GI) vasculitis in SLE has a good outcome with early diagnosis and intervention. Our patient responded well with surgery, steroid and belimumab, a fully human recombinant immunoglobulin G (IgG) 1λ monoclonal antibody. This case report showed that belimumab is a good alternative treatment for lupus GI vasculitis.
Lupus Erythematosus, Systemic ; Lupus

No abstract available.
Lupus Erythematosus, Systemic

No abstract available.
Enteritis* ; Lupus Erythematosus, Systemic*

No abstract available.
Lupus Erythematosus, Systemic* ; Psoriasis*

No abstract available.
Erythema ; Lupus Erythematosus, Cutaneous

No abstract available.
Humans ; Lupus Erythematosus, Discoid*

No abstract available.
Endocarditis* ; Lupus Erythematosus, Systemic*

No abstract available.
Lupus Erythematosus, Cutaneous*

Study on 99 patients with systemic lupus erythematosus (SLE) who were diagnosed and treated at Dermatology hospital, and all patients had surveyed genotype of FC gamma RIIA. The control group consisted of 93 voluntary blood donors who were surveyed genotype of FCRIIA. Genotype of FCRIIA was defined by PCR-SSP method. Results: 4 PCR reactions were used to determine genotype of FCRIIA. The frequency of R/R131, R/H131 and H/H131 in 99 patients occurred in 15 (15.1%), 74 (74.1%) and 10 (10.1%), respectively and in 93 control persons were 11 (11.8%), 50 (53.8%) and 32 (34.4%), respectively. The distribution of frequency of 3 genotype between 2 groups was different with 2 = 16.16 and p<0.01. Genotype of FCRIIA could be the risk factors for the appearance of SLE in Vietnamese people.
Lupus Erythematosus, Systemic ; Diagnosis

No abstract available.
Lupus Erythematosus, Systemic*